CD24 and neoplasm: Breast Cancer Stem Cells (BCSCs) were initially described in 2003 by Al-Hajj and colleagues, who found that the CD44+CD24−/lowLin− fraction was significantly enriched for cells with tumor forming ability as compared to the CD44+CD24+Lin− population.